John Beadle

1.2k total citations
24 papers, 731 citations indexed

About

John Beadle is a scholar working on Genetics, Oncology and Biotechnology. According to data from OpenAlex, John Beadle has authored 24 papers receiving a total of 731 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 10 papers in Oncology and 7 papers in Biotechnology. Recurrent topics in John Beadle's work include Virus-based gene therapy research (12 papers), CAR-T cell therapy research (9 papers) and Cancer Research and Treatments (7 papers). John Beadle is often cited by papers focused on Virus-based gene therapy research (12 papers), CAR-T cell therapy research (9 papers) and Cancer Research and Treatments (7 papers). John Beadle collaborates with scholars based in United Kingdom, United States and Australia. John Beadle's co-authors include Andrew J.S. Coats, Stephan von Haehling, Brian Champion, Stefan D. Anker, Ramón Salazar, Emiliano Calvo, Gwo Fuang Ho, Leonard W. Seymour, Kerry D. Fisher and R. H. Brown and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

John Beadle

23 papers receiving 700 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Beadle United Kingdom 12 297 277 246 206 104 24 731
Chin‐Wen Lai United States 10 291 1.0× 181 0.7× 162 0.7× 56 0.3× 123 1.2× 13 727
Arijita Jash United States 12 314 1.1× 104 0.4× 84 0.3× 68 0.3× 62 0.6× 21 709
U. Weyer Germany 13 443 1.5× 149 0.5× 62 0.3× 196 1.0× 31 0.3× 19 894
Hiroaki Segawa Japan 15 537 1.8× 119 0.4× 55 0.2× 105 0.5× 53 0.5× 19 1.0k
Olivia I. Koues United States 12 645 2.2× 153 0.6× 180 0.7× 134 0.7× 79 0.8× 19 1.0k
H Y Naim Switzerland 16 259 0.9× 285 1.0× 28 0.1× 73 0.4× 61 0.6× 21 680
Joern Pezoldt Germany 14 336 1.1× 138 0.5× 105 0.4× 66 0.3× 57 0.5× 23 877
José B. Sáenz United States 13 289 1.0× 80 0.3× 104 0.4× 28 0.1× 44 0.4× 19 776
Herbert B. Herscowitz United States 13 234 0.8× 195 0.7× 153 0.6× 52 0.3× 63 0.6× 46 826
Lennard W. Duck United States 14 426 1.4× 221 0.8× 48 0.2× 46 0.2× 54 0.5× 26 840

Countries citing papers authored by John Beadle

Since Specialization
Citations

This map shows the geographic impact of John Beadle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Beadle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Beadle more than expected).

Fields of papers citing papers by John Beadle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Beadle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Beadle. The network helps show where John Beadle may publish in the future.

Co-authorship network of co-authors of John Beadle

This figure shows the co-authorship network connecting the top 25 collaborators of John Beadle. A scholar is included among the top collaborators of John Beadle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Beadle. John Beadle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lillie, Tom, Andrew Stone, R. H. Brown, et al.. (2020). 329 Prolonged overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in SPICE, a phase I study of enadenotucirev in combination with nivolumab. SHILAP Revista de lepidopterología. A202.1–A202. 2 indexed citations
2.
Machiels, Jean‐Pascal, Ramón Salazar, Sylvie Rottey, et al.. (2019). A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). Journal for ImmunoTherapy of Cancer. 7(1). 20–20. 72 indexed citations
3.
García‐Carbonero, Rocio, Ramón Salazar, Ignacio Durán, et al.. (2017). Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. Journal for ImmunoTherapy of Cancer. 5(1). 71–71. 122 indexed citations
4.
Di, Ying, Maxine Bauzon, Janet Lei-Rossmann, et al.. (2017). Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus. Molecular Therapy — Oncolytics. 5. 62–74. 40 indexed citations
5.
Di, Ying, Hugo Calderón, Gray Kueberuwa, et al.. (2016). Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators. Molecular Therapy — Oncolytics. 4. 18–30. 43 indexed citations
6.
7.
Harb, Wael A., Virginie Cérec, Brian Champion, et al.. (2016). A phase I study of pembrolizumab in combination with enadenotucirev (EnAd) (SPICE) in subjects with metastatic or advanced carcinoma.. Journal of Clinical Oncology. 34(15_suppl). TPS3112–TPS3112. 3 indexed citations
8.
Calderón, Hugo, et al.. (2014). Evaluation of Enadenotucirev (ColoAd1), an oncolytic Ad11/Ad3 chimeric group B adenovirus, in combination with chemotherapeutic agents in a murine model of ovarian cancer. Human Gene Therapy. 25. 1 indexed citations
9.
Champion, Brian, et al.. (2014). "Arming" the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours. Journal for ImmunoTherapy of Cancer. 2(S3). 1 indexed citations
10.
11.
García‐Carbonero, Rocio, Marta Gil-Martín, Emiliano Calvo, et al.. (2014). A phase 1 mechanism of action study of intratumoral or intravenous administration of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus in colon cancer patients undergoing resection of primary tumor.. Journal of Clinical Oncology. 32(15_suppl). TPS3112–TPS3112. 5 indexed citations
12.
Calvo, Emiliano, Marta Gil-Martín, Jean‐Pascal Machiels, et al.. (2014). A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumors.. Journal of Clinical Oncology. 32(15_suppl). 3103–3103. 14 indexed citations
13.
14.
15.
Palus, Sandra, Anika Tschirner, Stephan von Haehling, et al.. (2013). Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia. International Journal of Cardiology. 170(2). 160–166. 20 indexed citations
16.
17.
Jones, Suzanne, Michaela Sharpe, John Oxford, et al.. (2009). DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine. 27(18). 2506–2512. 110 indexed citations
18.
Beadle, John. (2004). . Small Axe A Caribbean Journal of Criticism. 16. 119–124.
19.
Beadle, John, et al.. (2003). Electrophoretic Karyotype Analysis in Fungi. Advances in applied microbiology. 53. 243–270. 28 indexed citations
20.
Tofler, Geoffrey H., James Stec, John Beadle, et al.. (2000). The Effect of Vitamin C Supplementation on Coagulability and Lipid Levels in Healthy Male Subjects. Thrombosis Research. 100(1). 35–41. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chin‐Wen Lai Breakdown of academic impact, for papers by Arijita Jash Breakdown of academic impact, for papers by U. Weyer Breakdown of academic impact, for papers by Hiroaki Segawa Breakdown of academic impact, for papers by Olivia I. Koues Breakdown of academic impact, for papers by H Y Naim Breakdown of academic impact, for papers by Joern Pezoldt Breakdown of academic impact, for papers by José B. Sáenz Breakdown of academic impact, for papers by Herbert B. Herscowitz Breakdown of academic impact, for papers by Lennard W. Duck
Rankless by CCL
2026